NCT00446381View on ClinicalTrials.gov

Effect of Macugen(Pegaptanib)on Surgical Outcomes and VEGF Levels in Diabetic Patients With PDR (Diabetic Retinopathy or CSDME (Macular Edema)

NACompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

September 30, 2008

Study Completion Date

September 30, 2008

Conditions
Proliferative Diabetic RetinopathyDiabetic Macular Edema
Interventions
DRUG

Macugen (pegaptanib)

Pegaptanib 0.3 mg by intravitreal injection once pre-operatively

DRUG

Macugen (Pegaptanib)

Pegaptanib 0.3 mg by intravitreal injection once pre-operatively.

Trial Locations (1)

N6A 4G5

Ivey Eye Institute, St. Joseph's Health Care Centre, London

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

OTHER